P Lomalisa1, T Smith, F Guidozzi. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Johannesburg Hospital and University of the Witwatersrand, 7 York Road, Parktown, Johannesburg, 2193, South Africa.
Abstract
PURPOSE: The goal of this study was to determine whether South African HIV-seropositive women with invasive cervical cancer present with disease that is more advanced than that of HIV-seronegative women and whether degree of immunosuppression affects the extent of disease at initial presentation. METHODS: This study is a retrospective review of 60 HIV-seropositive and 776 HIV-seronegative new cases of invasive cervical carcinoma seen at the combined gynecologic oncology unit of the University of the Witwatersrand, Johannesburg, South Africa. RESULTS: The HIV seroprevalence was 7.2%. Squamous cell carcinoma was the histologic subtype in more than 90% of both cohorts of patients. Although the HIV-positive patients presented with invasive cervical cancer almost 10 years earlier than the HIV-negative patients, i.e., mean age 44 years +/- 9.8 versus 53 years +/- 12.7, respectively (P </= 0.001), there was no difference in the distribution of advanced lesions in the two groups, i.e., 65% in HIV-positive and 55.4% in HIV-negative patients (P = 0.177). At initial diagnosis 26 of the HIV-seropositive patients had a CD(4) cell count less than 200/mm(3), 20 (77%) of whom presented with stage III or IV cervical cancer; the remaining 34 had a CD(4) cell count above 200/mm(3), 19 (56%) of whom had advanced-stage disease. This was not significantly different (P = 0.109). However, HIV-seropositive patients with CD(4) cell counts less than 200/mm(3) had significantly more advanced-stage disease than HIV-seronegative patients, i.e., 77% versus 55.8% respectively (P = 0.041). CONCLUSION: HIV-seropositive patients presented with invasive cervical cancer almost 10 years earlier than HIV-seronegative patients. Even though HIV seropositivity on its own did not appear to adversely affect extent of disease at presentation, patients with CD(4) cell counts below 200/mm(3) are significantly more likely to have advanced-stage disease at initial diagnosis than HIV-negative patients. Copyright 2000 Academic Press.
PURPOSE: The goal of this study was to determine whether South African HIV-seropositivewomen with invasive cervical cancer present with disease that is more advanced than that of HIV-seronegative women and whether degree of immunosuppression affects the extent of disease at initial presentation. METHODS: This study is a retrospective review of 60 HIV-seropositive and 776 HIV-seronegative new cases of invasive cervical carcinoma seen at the combined gynecologic oncology unit of the University of the Witwatersrand, Johannesburg, South Africa. RESULTS: The HIV seroprevalence was 7.2%. Squamous cell carcinoma was the histologic subtype in more than 90% of both cohorts of patients. Although the HIV-positive patients presented with invasive cervical cancer almost 10 years earlier than the HIV-negative patients, i.e., mean age 44 years +/- 9.8 versus 53 years +/- 12.7, respectively (P </= 0.001), there was no difference in the distribution of advanced lesions in the two groups, i.e., 65% in HIV-positive and 55.4% in HIV-negative patients (P = 0.177). At initial diagnosis 26 of the HIV-seropositivepatients had a CD(4) cell count less than 200/mm(3), 20 (77%) of whom presented with stage III or IV cervical cancer; the remaining 34 had a CD(4) cell count above 200/mm(3), 19 (56%) of whom had advanced-stage disease. This was not significantly different (P = 0.109). However, HIV-seropositivepatients with CD(4) cell counts less than 200/mm(3) had significantly more advanced-stage disease than HIV-seronegative patients, i.e., 77% versus 55.8% respectively (P = 0.041). CONCLUSION:HIV-seropositivepatients presented with invasive cervical cancer almost 10 years earlier than HIV-seronegative patients. Even though HIV seropositivity on its own did not appear to adversely affect extent of disease at presentation, patients with CD(4) cell counts below 200/mm(3) are significantly more likely to have advanced-stage disease at initial diagnosis than HIV-negative patients. Copyright 2000 Academic Press.
Authors: Georgette Adjorlolo-Johnson; Elizabeth R Unger; Edith Boni-Ouattara; Kadidiata Touré-Coulibaly; Chantal Maurice; Suzanne D Vernon; Marcel Sissoko; Alan E Greenberg; Stefan Z Wiktor; Terence L Chorba Journal: BMC Infect Dis Date: 2010-08-17 Impact factor: 3.090
Authors: Cynthia Firnhaber; Khumbuzile Zungu; Simon Levin; Pam Michelow; Luis J Montaner; Patrick McPhail; Anna-Lise Williamson; Bruce R Allan; Charlie Van der Horst; Allen Rinas; Ian Sanne Journal: Acta Cytol Date: 2009 Jan-Feb Impact factor: 2.319
Authors: Jennifer R Moodley; Margaret Hoffman; Henri Carrara; Bruce R Allan; Diane D Cooper; Lynn Rosenberg; Lynette E Denny; Samuel Shapiro; Anna-Lise Williamson Journal: BMC Cancer Date: 2006-05-23 Impact factor: 4.430
Authors: Innocent O Maranga; Lynne Hampson; Anthony W Oliver; Xiaotong He; Peter Gichangi; Farzana Rana; Anselmy Opiyo; Ian N Hampson Journal: Open Virol J Date: 2013-02-25